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Abstract: The rapid expansion of consumer sleep devices is outpacing the validation data 
necessary to assess the potential use of these devices in clinical and research settings. Common 
sleep monitoring devices utilize a variety of sensors to track movement as well as cardiac and 
respiratory physiology. The variety of sensors and user-specific factors offer the potential, at 
least theoretically, for clinically relevant information. We describe the current challenges for 
interpretation of consumer sleep monitoring data, since the devices are mainly used in non-
medical contexts (consumer use) although medically-definable sleep disorders may commonly 
occur in this setting. A framework for addressing questions of how certain devices might be 
useful is offered. We suggest that multistage validation efforts are crucially needed, from the 
level of sensor data and algorithm output, to extrapolations beyond healthy adults and into other 
populations and real-world environments.
Keywords: movement, cardiac and respiratory physiology, sensor, consumer sleep monitoring 
data
Introduction
Wearable technology for health and wellness tracking is expanding rapidly in the con-
sumer space – perhaps faster in some cases than the medical community can assess 
potential risks and benefits of these advances. A variety of sensor technologies have 
been applied specifically to monitor sleep–wake patterns. Some of these technologies 
claim to improve sleep, either via “sleep-coach” features or by the implication that 
simply tracking one’s sleep will result in discovery of patterns that can lead to sleep 
improvements. Consumer demand for sleep monitors is striking, with the market 
apparently sufficient to support numerous companies active in this space, as well as 
frequent new additions from a pipeline that enjoys rapid technical and computational 
advances.
Despite extensive published experience with the limitations of wrist actigraphy for 
quantifying sleep, most of the currently available monitoring devices are actigraphy-based 
yet purport to accurately measure sleep. To place the marketing trends and consumer 
demand into perspective, we note that a consumer sleep monitor with no published 
validation was listed among Time Magazine’s inventions of the year in 2005,1 decades 
after wrist actigraphy had been introduced for sleep tracking. The combination of con-
sumer demand and potential or perceived wellness benefits of sleep monitors seems to 
overshadow the limitations and lack of validation, as recently reviewed2 (some criticisms 
have been voiced in the academic3,4 as well as legal settings5). The recently increased 
involvement of large technology companies like Apple and Intel (the latter acquired the 
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Basis watch) in sleep monitoring may lend further legitimacy 
to the idea of consumer-facing sleep monitors.
The current landscape of marketing claims that stretch 
beyond the scant validation literature may contribute to the 
discrepancy between consumer and health care community 
adoption of sleep monitoring devices. Clinicians and research-
ers, more familiar with the extensive experience and validation 
of polysomnography (PSG) and actigraphy, may be hesitant 
to become early adopters pending rigorous validation, which 
may not be prioritized for devices that do not intend to make 
medical claims. Wellness claims are necessarily vague, and 
as a result, government oversight is limited from a medical 
use perspective. In this review, we explore the developments 
in consumer sleep monitoring technology, identify valida-
tion issues in this space, and speculate on potential clinical 
utility. That sleep conceptually straddles an increasingly 
blurry boundary between sleep as a medical field and sleep as 
“wellness” emphasizes the need for a framework to interpret 
consumer sleep device outputs across this spectrum.
Consumer sleep monitors: what 
they measure, and what they claim
The most basic type of sensor used in consumer sleep moni-
tors is movement detection, often based on wrist actigraphy. 
The algorithm output of devices in this class (Table 1) may 
subdivide sleep into “light” or “deep” phases (eg, Jawbone 
and Fitbit), presumably based on the degree of detected 
movement. Sensor technology has more recently expanded 
to incorporate physiological measures beyond actigraphy, 
such as heart rate and/or respiration patterns (Table 1). 
Priced similarly to some of the popular wrist movement 
devices, these devices contain more advanced sensing 
methods, some of which claim to distinguish rapid eye 
movement (REM) and non-REM (NREM) sleep substages. 
Two wrist devices monitor heart rate in addition to actigra-
phy and use this information to stage REM and NREM sleep 
(Basis, Jawbone UP3). FitBit has a model that reports heart 
rate, but it is not clear that this information is used in the 
sleep staging algorithm. Other cardiopulmonary monitors 
for tracking sleep can be either worn on the body (as a shirt 
with embedded sensors, such as the Hexoskin), or placed in 
the bedroom for passive data collection, such as on the mat-
tress (eg, Beddit). The totally noncontact sensing of respira-
tion pattern (ResMed S+) is also available and reports REM 
and NREM sleep stages based on stage-specific breathing 
patterns, which were seen even in the earliest descrip-
tions of REM sleep.6 Each provides a sleep score (usually 
0–100 scale), based on some combination of features such 
Table 1 Overview of common consumer sleep monitors
Device Sensor Sleep Output Validation Web site claims
Basis Peak36 Wrist actigraphy and Hr W, reM, light Nr,  
deep Nr
N=12 healthy adults,  
versus PSG
“The ultimate fitness  
and sleep tracker”
Beddit37,** Mattress sensor for  
respiration and Hr
W, S (“depth”) validation of sensors “the ultimate sleep guide”
FitBit38,** Wrist actigraphy (+/- Hr*) W, S (depth of sleep) N=24 healthy adults,  
versus PSG
“Sleep better and live well… 
automatically track your sleep”
Garmin Vivofit39 Wrist actigraphy (+/- Hr*) W, S N/A “Monitor your rest”
Hexoskin40 tight shirt, embedded sensors  
for respiration and Hr
W, S validation of sensors “the ultimate sleep  
tracking device”
Jawbone (UP3)41,** Wrist actigraphy,  
respiration, Hr
W, reM, light Nr,  
deep Nr
N/A “the world’s most  
advanced tracker”
Lark Pro42,** Wrist actigraphy W, S N/A “Our software trains  
you to sleep better”
Misfit Shine43,** Wrist actigraphy W, S (“depth”) N/A “Sleep quality and duration”
resMed S+44,** radar-like respiration  
tracking
W, reM, light Nr,  
deep Nr
N=74 some healthy some  
OSA adults, versus PSG
“track and improve your  
sleep from the very first night”
reston45 Mattress pressure sensor  
for respiration and Hr
W, S (“depth”) N/A “Medical-grade accuracy…  
helps you achieve your  
best sleep each night”
Sleeprate46 Polar heart band + App W, reM, light Nr,  
deep Nr
N/A “Assesses the underlying  
causes of any sleep issues”
Sleep tracker47,** Wrist actigraphy W, S N=18 healthy adults,  
versus PSG
“Monitors your sleep patterns  
to help you wake up feeling  
refreshed”
Withings Aura48,** Mattress pressure sensor  
for respiration and Hr
W, reM, light Nr,  
deep Nr
N/A “expert at helping you fall  
asleep faster”
Notes: * indicates sleep algorithm is based on movement. ** indicates smart alarm feature.
Abbreviations: Hr, heart rate; W, wake; S, sleep; Nr, non-reM, reM, rapid eye movement; PSG, polysomnography, NA, not available.
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as total sleep duration, “depth” or fragmentation; none 
of the scoring quality methods has been validated. The 
devices differ in battery charging requirements and water 
resistance (Table S1). Figure 1 illustrates example outputs 
from some of the devices, representing a spectrum of sensor 
technologies, recorded simultaneously with gold standard 
measurements from PSG or formal actigraphy. A visual 
comparison between outputs among the different consumer 
devices, and between each consumer device and the gold 
standards, highlights the need for careful evaluation of 
what kinds of information the monitors provide, and how 
that information compares and/or complements currently 
accepted methodologies.
Although many of the available consumer devices offer 
a smart-alarm feature (Table 1), none has been validated 
for this purpose. Smart alarms are based on the concept 
that the stimulus to awaken should be delivered when one 
is naturally transitioning to light sleep or wakefulness to 
avoid potential grogginess that may be associated with 
awakening from deeper NREM sleep stages. Instead of 
experimental validation, the marketing claims seem to be 
relying on face validity: the intuition that an alarm should 
align with times when one is already practically awake. 
A more appropriate term might be “transitive property 
validation”, because what makes the idea seem valid 
resides in some approximately related research. For the 
smart alarm, the reasoning might be: sleep inertia occurs 
in some people when awakened from slow wave sleep, so 
if the device alarm targets periods of movement, which 
rarely occur in deep sleep, then sleep inertia can be avoided 
and instead one awakens feeling more energetic. A recent 
study of a smart-phone app that performed similarly to 
actigraphy for gauging sleep versus wake in healthy adults 
failed to demonstrate the effectiveness of the smart-alarm 
feature.3
The common implication across the marketing of 
consumer sleep monitors is that tracking sleep will lead to 
improved sleep. The claims are not intended to be “medi-
cal” in nature, such that the validation standards normally 
applied to medically used devices are not required, and 
accordingly the marketing content often includes caveats in 
this regard. However, the language found on the web sites 
can range from fairly benign (Garmin: “monitor your rest”) 
to rather hyperbolic (Reston: “most accurate sleep monitor 
ever”) (Table 1). Information available on the internet may 
influence consumer confidence, and certain language can 
come across as scientifically or medically valid. Consider as 
an example that FitBit’s chief technology officer was quoted 
in the USA Today regarding an individual for whom their 
device detected 83 wake-ups, which prompted the user to 
get tested for obstructive sleep apnea (OSA), adding that 
FitBit hears such stories “all the time”.7 This device is 
not validated for any medical purpose, and certainly not 
intended to screen for OSA, yet such public anecdotes 
(especially from company leadership) may send a different 
message to consumers. The mismatch between marketing 
content and supporting validation makes answering the 
seemingly straightforward question more challenging: is 
there any potential use for consumer sleep devices in sleep 
medicine?
REM
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Deep
Light
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Figure 1 comparison of sleep architecture across monitoring modalities.
Notes: Manually aligned output from gold standard PSG scoring (A), formal actigraphy (F), Actiwatch Spectrum; vertical lines indicate movement amount in 30 second bins, 
as well as four consumer sleep monitors worn concurrently by an adult male in the sleep lab (B) resMed S+; (C) Basis; (D), Beddit; (E), Jawbone. the time bar on the bottom 
applies to all rows. the sleep stages reported by each modality is shown on the left; an image of the technology is shown on the right.
Abbreviations: reM, rapid eye movement; PSG, polysomnography.
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Sleep and the blurred boundary  
of wellness and medicine
Motivations for using consumer sleep monitors are surely 
diverse and could range from simple curiosity to wellness 
goals like self-improvement through optimizing sleep 
patterns. Perhaps more concerning to physicians are the 
individuals with sleep-related concerns who seek some 
explanation or improvement via consumer devices before (or 
instead of) seeking medical advice. Consumers encounter-
ing the optimistic marketing claims of these sleep devices 
might not recognize the limitations and might even wonder 
why doctors do not use these devices more often in their 
practice. Providers, by contrast, are typically aware that 
even “medical-grade” actigraphy enjoys clinical utility in 
only limited situations,8 such as assessing circadian rhythm 
disorder patterns in those who cannot or will not provide diary 
data, or verifying adequate sleep opportunity in the nights 
preceding a multiple sleep latency test. Providers might be 
skeptical of what is seen as largely unvalidated marketing 
claims and thus the potential utility of the devices remains 
questionable.
Although the wellness claims do not require regulation 
typical of medical devices, the practical issues raised by 
devices used at the interface of health care and wellness 
remain challenging. Primary sleep disorders have protean 
manifestations, and symptoms potentially attributable to poor 
sleep tend to be nonspecific. The boundary between sleep 
as wellness and sleep as a medical concern is hardly clear, 
and the overlap impacts interpretation of consumer device 
outputs. By comparison, even medically validated diagnostic 
technologies are at risk for false positive and false negative 
results. Such risks are influenced by the Bayesian triad of 
sensitivity, specificity, and pretest probability of the disease 
in question.9 Likewise, the potential for false positive and 
false negative outcomes can be understood if we consider 
consumer sleep devices in this framework.
Figure 2 illustrates the potential for confusion regarding 
device performance accuracy across a simplified context 
often invoked to understand diagnostic testing: dichotomous 
health status (here, the presence or absence of an objective 
sleep disorder), and the dichotomous presence or absence 
of sleep-related symptoms. Consider an asymptomatic indi-
vidual who uses a consumer sleep device, and is faced with 
interpreting the sleep “score” output. A poor score would be 
a false alarm if the person in fact had healthy sleep, while 
a good score would be a false reassurance if the person in 
fact had an occult primary sleep disorder. The asymptomatic 
individual might not appreciate that occult sleep disorders are 
not uncommon, and thus not appreciate that false negative 
results are possible.
On the other hand, an individual with symptoms that 
could in principle be related to a sleep disorder is presented 
with a similar interpretation challenge. A good sleep score 
from a consumer device could represent false reassurance if 
a primary disorder is present, or it could be accurate if sleep 
was in fact healthy but the symptom (such as fatigue) had a 
nonsleep underlying cause (such as undiagnosed depression 
or hypothyroidism). By contrast, a poor sleep score in this 
setting could falsely steer the individual toward clinical sleep 
investigations and potentially delay diagnosis of the actual 
underlying problem.
The consumer knows which row to consider when inter-
preting their sleep score (ie, whether they have symptoms 
potentially linked to poor sleep), but they do not know the 
probability of their true sleep status being in the healthy ver-
sus affected column (Figure 2). Thus, within each row, four 
possible interpretations exist for each individual using a sleep 
monitor, encompassing true and false positives, and true and 
false negatives. The probability of objective sleep disorder pres-
ence, known as the prior or pretest probability, is a necessary 
step to interpret any test result, such as the output of a consumer 
device. The other required pieces of information, sensitivity 
and specificity for discriminating healthy and affected states, 
are also not known, although the marketing language may lead 
consumers to believe that the outputs can accurately detect 
problems. Although a provider might have an intuition for the 
pretest probability, they have little validation data to navigate 
the uncertainty surrounding the accuracy of the device for 
quantifying any sleep disturbance in a clinical setting.
There are of course many other possibilities not captured 
by the dichotomies that are shown in Figure 2. Consider an 
FN TP TN FP
FN TP TN FP
S
ym
p
to
m
s
Objective sleep status  
Sleep disorder present 
Has symptoms 
Has objective problem
“Nonspecific symptoms”
Has symptoms 
No objective problem
“Asymptomatic sleep problem”  True healthy” 
No symptoms No symptoms
Has objective problem No objective problem 
Healthy sleep 
Ye
s
No
“Symptomatic sleep problem”
“
Figure 2 Schematic representation of symptoms, sleep health status, and consumer 
monitor output.
Notes: Dichotomous presence of symptoms (rows) and objective sleep disorder 
(columns) are shown to illustrate four possible scenarios (quoted text in each box). 
For each scenario, the output of a consumer sleep monitor, when considered as a 
dichotomous result, can be either a true (green shading) or a false (red shading) 
finding.
Abbreviations: tP, true positive; tN, true negative; FP, false positive; FN, false 
negative.
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individual who uses a consumer monitor that detects snoring. 
Upon reviewing the monitor’s data suggesting that snoring is 
occurring, the individual then looks on the internet for snor-
ing interventions, and learns that nasal spray or breathe-right 
strips may help. This may sound innocent enough, but the 
potential downside is clear: the person with snoring may or 
may not have OSA, and the consumer sleep monitor would 
not answer this important question. Perhaps of greater con-
cern, if OSA was in fact present, an over-the-counter inter-
vention that actually reduced the snoring would be unlikely 
to meaningfully reduce the OSA severity. Therefore, if the 
device output suggested reduced snoring, then false reassur-
ance may occur unless the individual recognizes the potential 
accuracy limitations of snore detection, as well as the dis-
sociation between snoring metrics and OSA severity metrics. 
How might a snore detection device be used more sensibly? 
Although one might use snoring as one component of a risk 
stratification approach, to place the issue of snore detection10 
into context, consider that the entire eight question STOP-
Bang screening tool,11 of which snoring is just one question, 
has only modest screening value,9 and had somewhat lower 
performance in other clinical studies.12
Given this uncertainty, it is currently unclear how indi-
vidual patients or providers might utilize data from consumer 
devices. One major concern is that consumers may conflate 
the rows and columns of Figure 2, assigning symptom 
presence/absence as if it meant sleep disorder presence/
absence. Together with possibly over-estimating device 
accuracy, this leads to problems at all levels of Bayesian 
inference when interpreting device outputs. At the popula-
tion level, without knowing how many individuals fall into 
each of these categories, the scope of false reassurance, false 
concern, or true health status cannot be estimated. Important 
questions remain thus unanswered: How often do individuals 
first present to their physician seeking sleep evaluation based 
on consumer sleep device data? What portion of individuals 
who use consumer sleep monitors make a health care-related 
decision based on the data? What portion of the physicians 
(sleep specialists or otherwise) feel confident in interpreting 
the results of consumer devices?
Claim-validation mismatch: the 
many faces of “validation”
Validation is a broad concept, the details of which are use-
ful to consider in the context of consumer sleep devices. 
Vernacular use of the word validity implies a sense of 
legitimacy such as might be achieved by testimonials, 
endorsement, or the “obviousness” known as face validity. 
We have discussed that transitive property validation is also 
common in the consumer space. These aspects of validation 
may be useful first steps, but are insufficient to address the 
potential utility of devices for clinical or research endeavors. 
Figure 3 describes different levels of validation to provide a 
framework for considering the potential utility of consumer 
sleep devices, and how validation can be achieved. Even 
when apparent validation data are available for a device, it 
is important to parse out the details regarding what aspect 
of sleep is being assessed by the sensors and the algorithms, 
what population was tested and in what context, and what 
external factors (sleep or medical disorders, alcohol, etc) 
might influence the performance in a clinical population. 
Because sleep is not a monolithic entity, any validation 
experiment or claim of a sleep monitor should be contextual-
ized by specifying the device feature being assessed and the 
gold standard reference, in addition to other details of the 
study design and statistics.
Essentially all consumer sleep devices can make claims 
within the minimal validation context of face validity or tran-
sitive property validity. The next step would be comparison 
of device performance against a gold standard, such as PSG 
or actigraphy. This important step should itself be subdivided, 
because the experimental approach could refer to the sensor 
itself (does it accurately measure the aspect of physiology it 
purports to measure), the algorithm used to map the sensed 
physiology to some output (such as sleep stage), and perhaps 
whether a novel metric is being related to a standard metric 
(eg, depth instead of stage). Few devices have published 
data in this category of validation against a gold standard 
in healthy individuals. Even at the sensor level, two devices 
ostensibly measuring the same aspect of human physiology 
might not be functionally equivalent in their hardware or 
software components. Previous studies have shown with 
actigraphy and pulse oximetry that the details of the particular 
sensors and algorithms impact device results.13,14 Presumably, 
the same issues would arise among consumer devices using 
a given technique, such as using wrist movement, to assess 
sleep–wake state.
The most important aspect of validation, however, is 
arguably to assess the robustness of the sensor and algorithm 
performance in settings beyond that of healthy adults in the 
sleep laboratory. External validity refers to the extent to 
which in-laboratory validation results can be extrapolated 
to populations that differed from those tested during the 
validation studies. For example, a laboratory validation of a 
consumer sleep monitor in healthy young adults might not 
extrapolate to device performance in an older population 
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with objective sleep disturbance recorded by laboratory 
PSG. Ecological validity is a related concept, referring to 
the extent to which validation results can be extrapolated 
to different environments than those used during validation 
studies. For example, a laboratory validation of a consumer 
device in a population with objective sleep disturbance 
might not extrapolate to device performance when used by 
such patients in their homes. Further, user-specific factors 
such as differences in body position, tightness of the device, 
position of the device on the body (for wearables) or near 
the body (for noncontact sensors), or other behaviors might 
impact device outputs as well, even for devices that have 
been experimentally validated in certain settings, such as a 
controlled laboratory environment. The presence of a bed 
partner may impact sensor function or algorithm processing 
accuracy, perhaps more so if a sleep disorder is present in 
the partner.
Consumer sleep monitor validity: 
reframing the questions
Once the uncertainties regarding consumer device validation 
are appreciated, we can better address the question of what 
kinds of information, if any, could be reasonably extracted 
from these monitors to support clinical decision-making? 
The answer might depend on several patient-specific  factors 
(type and severity of sleep disorder, comorbidities or medica-
tions, comfort level with different aspects of technology) and 
device-specific factors (type of sensor, algorithm accuracy 
for different aspects of sleep physiology and pathophysiol-
ogy). In addition, user-specific factors and user-errors also 
play into the interpretation of consumer device data, such 
as how the device is worn (for wearable items) or where it 
is positioned on or near the bed (for the passive or noncon-
tact monitors), or whether a bed partner is present. Even an 
apparently simple issue like needing to remember to start 
or stop recording could lead to nonrandom data loss during 
longitudinal home monitoring (eg, an individual might be 
more likely to forget to start recording when tired, or if alco-
hol was consumed). Consumer sleep devices that are easy 
to implement, or automatically start/stop recording, might 
allow for an increased likelihood of adherence. Recording 
multiple nights of data can capture night to night variability, 
avoid the first night effect that may occur in the laboratory 
setting, and facilitate pattern recognition linking sleep-
related measurements with other behaviors (eg alcohol, 
medications, exercise).
Device aspect Gold standard 
Sensor
(eg, radar)
PSG
(eg, effort belts)
Algorithm
(eg, radar to stages)
Human expert
(eg, manual staging)  
Novel metric
(eg, sleep score)
Clinical outcome
(eg, sleepiness)
Face
validity
Transitive
validity 
External
validity
(different
populations)
Core
validation
(comparison
against PSG or
actigraphy)  
Ecological
validity
(different
environments)
Figure 3 Stages of validation for consumer sleep monitors.
Notes: the most basic forms of validation (face and transitive validity) are philosophical constructs that typically motivate experimental validation against a gold standard such 
as PSG or actigraphy (middle dashed rectangle). this core validation is subdivided into at least three device aspects, each of which requires distinct experimental approaches. 
None of the existing consumer devices reach the key validation arms of external and ecological validity (right dashed rectangle).
Abbreviation: PSG, polysomnography.
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By specifying potential goals for use of consumer sleep 
devices, one can develop a framework for assessing which 
devices, if any, could theoretically meet the goals, and thus 
inform how to undertake validation. Potential solutions surely 
will differ depending on context at the level of individual 
patient care decisions, versus large-scale epidemiological 
studies that combine self-reported health queries and objec-
tive monitoring. We will consider several categories of 
potential utility of consumer sleep devices (Table 2).
can a consumer device replace or 
complement a diary of sleep and  
wake times?
For individuals who cannot or will not adhere to manu-
ally tracking their sleep and wake times, a device could 
theoretically substitute, if it was easy to use or had 
automated assessments of time in bed. Most currently 
available devices require the user to indicate when they 
are in bed trying to sleep, which itself requires some 
degree of adherence. From an epidemiology perspective, 
sleep duration is typically self-reported as an average or 
habitual estimate, and has led to speculation in regard to 
associations with long and short duration reports.15,16 Self-
reported sleep–wake durations, especially in those with 
sleep complaints like insomnia, are well-known to contain 
a variety of uncertainties.17 The question of how important 
the single facet of sleep duration may be for health is itself 
influenced by the nature of self-report; the technological 
advances of consumer sleep monitors hold promise for 
bringing objectivity and multi-night sampling to bear on 
this most basic epidemiological query.
can a consumer device replace formal 
actigraphy?
The answer here depends on what aspect of actigraphy is 
desired. For gross patterns of time in bed versus time out of 
bed, nearly all of the devices on the market could accomplish 
this. For quantitative analysis of movements, and translating 
the sensor data into scoring of sleep/rest periods, wrist-worn 
movement devices would be preferred over cardio-pulmonary 
monitors, and formal validation studies would be required. 
This would include comparing the device sensor (accel-
erometer) against gold standard actigraphy, as well as the 
algorithm output. If application of novel metrics is based 
on activity counts, such as scale invariant correlations18 or 
transition probability metrics,19 then, in addition, the capacity 
to export the raw movement signals would be required.
When formal actigraphy is used to track sleep patterns 
longitudinally in those with insomnia, perhaps to monitor 
therapeutic interventions, the same limitations applying 
to the interpretation of actigraphy data would be germane to 
the interpretation of a consumer device based on the wrist 
movement. Formal actigraphy tends to have high sensitivity 
and low specificity (approximately 90% and 50%, respec-
tively) for detecting sleep.20 Therefore, actigraphy can over-
estimate total sleep time for an insomniac, who may spend 
substantial time awake but not moving sufficiently to register 
with the algorithm. Individuals with primary underlying 
sleep disorders such as periodic limb movements or OSA 
might exhibit different performance accuracy of actigraphy 
analysis, yet actigraphy itself cannot detect these problems, 
so implementation of wrist actigraphy (by any device) should 
take this into consideration.
can a consumer device be useful for 
insomnia management?
Although objective testing is not routinely recommended for 
clinical management of insomnia, recent evidence argues 
for the potential utility of objective sleep measurements for 
several reasons, and at-home multi-night tracking may be 
particularly useful in this population.21 Epidemiology data 
incorporating objective testing suggest that medical22 and 
psychiatric23 risks studied prospectively require the combina-
tion of insomnia symptoms and short objective sleep duration 
on PSG – suggesting that insomnia phenotyping according to 
objective measures may be important for risk stratification, 
risk-benefit assessment of hypnotics, and even prospective 
Table 2 Use categories
Device Diary 
(TIB)
Rest–
activity 
cycles
Stages  
(REM versus 
NREM)
Disordered 
breathing
Basis Peak36 + + + -b
Beddit37 + - +a +c
FitBit38 + + - -
Garmin Vivofit39 + - - -b
Hexoskin40 + - +a +c
Jawbone (UP3)41 + + + -b
Lark Pro42 + - - -
Misfit Shine43 + + - -
resMed S+44 + - + +c
reston45 + - +a +c
Sleeprate46 + - + -b
Sleep tracker47 + + - -
Withings Aura48 + - + +c
Notes: aNot in current state, but theoretically could yield stages based on available 
sensors; bcertain heart rate variability metrics may be linked to sleep apnea; csleep 
apnea may be quantifiable by respiration movement patterns alone.
Abbreviations: tiB, time in bed; reM, rapid eye movement; NreM, non-reM.
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clinical trial design. Misperception among patients with 
chronic insomnia, which requires comparison of subjective 
report with objective measurement, could be better character-
ized with home monitoring to allow repeated measurements 
(is misperception a state or trait phenomenon?) and discover 
patterns. Feedback from sleep monitoring devices may be 
beneficial in patients with misperception.24 The growing 
risk concerns surrounding even intermittent hypnotic use, 
together with the limited data supporting medical benefit 
of these drugs, highlight the use of nonpharmacological 
approaches such as cognitive-behavioral therapy.25 Finally, 
increasing data suggesting occult sleep apnea occurs in 
patients with insomnia symptoms26–28 is a reminder that the 
choice of testing must consider the physiological realities 
beyond the clinical assessments that often channel patients 
to certain pathways.
can a consumer device be useful for 
tracking sleep stages?
The rich experimental literature linking REM and N3 to 
cognitive performance has not enjoyed wide practical clinical 
appreciation, in part because of limited tools to augment these 
stages, but also because of wide individual variability. The 
uncertainty in the clinical validity of these experimental links 
is highlighted by a recent large study of healthy adults finding 
no relationship of episodic memory to stage architecture.29 
Having reliable home monitoring of sleep stage architecture 
would allow individuals to test possible relationships them-
selves through a combination of diary entries, device outputs, 
and perhaps performance tracking. The use of autonomic 
physiology to estimate sleep stages traditionally defined 
by electroencephalography involves trade-offs, such as the 
benefits of ease of use and simplifying automation, versus the 
risks of reduced estimation accuracy compared with the gold 
standard. Assuming no untreated primary disorder was pres-
ent (such as occult OSA or occult periodic limb movements), 
an individual could in principle search for correlations over 
time, to answer two questions: are aspects of sleep architecture 
(stages, fragmentation, total duration) linked reliably to one 
or more aspects of daytime function (cognition, mood, etc), 
and are behaviors or experiences influencing sleep architec-
ture (caffeine, exercise, alcohol, stress). Such data could be 
powerful across the spectrum of wellness and health.
can a consumer device screen for  
sleep apnea?
Current methods of screening based on clinical features have 
limitations.9 However, objective testing with limited-channel 
devices for OSA diagnosis is explicitly excluded for general 
screening use by the American Academy of Sleep Medicine 
guidelines.30 Home monitoring might fill a niche here by adding 
an objective component to risk stratification. Analysis of single 
channels of data have already shown promise for quantifying 
sleep disordered breathing in certain settings,31–33 and also 
used to distinguish central from obstructive apnea.34 Whether 
a combination of clinical information and a consumer wearable 
device could provide risk stratification is a testable hypothesis. 
Devices using only wrist movement would be unlikely to serve 
this purpose, whereas devices that recorded cardiac or respira-
tory parameters could be the focus of future validation.
Conclusion
It is no surprise that consumer sleep devices provide only a sub-
set of the extensive physiology contained in laboratory PSG. 
Yet proper validation of these devices for specific purposes 
has strong potential for a variety of goals described earlier. 
The status quo, in which consumer devices contextualize their 
claims as “wellness”, can send conflicting messages, in which 
neither providers nor consumers can rationally navigate the 
device outputs (Figure 2). The more widely these products 
enjoy consumption, the more urgently important it is for all 
stakeholders to engage in resolving the current state of claim-
validation mismatch. Insurers are another group with potential 
interest in consumer devices for health tracking,35 and the same 
validation issues are germane to this perspective as well. The 
question remains whether devices can add value in clinical and 
research domains. Formal cost-effectiveness modeling will 
be informed by further validation data, as many factors have 
important influence such as device cost, technical robustness 
(failure rates), accuracy for the intended use, and downstream 
consequences of the actions based on device output. Although 
these are important concepts to consider, the time and resources 
required to establish external and ecological validity may not 
be prioritized in the consumer space, where even basic valida-
tion studies are often not available. Recognizing the validation 
limitations may nevertheless help pave the path forward. The 
widespread consumption of sleep monitors is a reminder that 
the stakes are high, and that prioritizing validation efforts, 
regardless of whether certain devices meet more rigorous 
medical standards, will be important for all stakeholder per-
spectives to understand the potential risks and benefits of sleep 
monitoring technology in the consumer space.
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Table S1 Operational features of common consumer sleep monitors
Device Location Charge duration Water resistance
Basis Peak36 On wrist 4 days Water resistant to 50 m
Beddit37 Under bedsheet Plug-in Not water resistant
FitBit38 On wrist 5 days Water resistant
Garmin Vivofit39 On wrist 1+ year Water resistant to 50 m
Hexoskin40 t-shirt 14–150 hours Machine washable
Jawbone (UP3)41 On wrist 7 days Splash proof
Lark Pro42 On wrist Daily charge required Not intended to be used near water
Misfit Shine43 On wrist No charging Waterproof to 50 m
resMed S+44 On nightstand Plug-in Not water resistant
reston45 Under bedsheet 30 days Not water resistant
Sleeprate46 On chest 200 hours Water resistant
Sleep tracker47 On wrist Not reported Water resistant up to 10 m
Withings Aura48 Under mattress Plug-in Not water resistant
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